US NIH authorizes first uses for genomic data from HeLa cells

- Last updated on GMT

NIH approved four projects that will use the famous HeLa cell line
NIH approved four projects that will use the famous HeLa cell line
A US NIH working group approved the first four projects looking to use genomic data from the infamous HeLa cell line.

Of the six data access requests, the HeLa Genome Data Access Working Group accepted one initially, three more after additional data was requested, and for two other projects the working group is looking for additional information.

The announcement of the projects and the group’s approvals -- which included consultation with descendants of Henrietta Lacks, the woman whose fatal cervical tumour cells brought about the cell line – follows long negotiations between the US agency and the Lacks family​.

The approved projects include:

-        Use of Haplotype Resolved HeLa Genome Sequence to Map Ribo-seq Reads for Inference of Allele-specific mRNA Translation Rates;

-        The Role of Cohesin and the Cohesin Loading Factor NIPBL in Transcriptional Regulation of HeLa Cells;

-        Computations Methods for Integrative Analysis of Omics Datasets; and

-        Cancer Haplomics: Computation of Haplotypes in the Presence of Polyploidy and Variable Copy Number.

The working group is looking to ensure that the proposed research is medically driven, not related to determining the ancestry or population origins of the cells or reliant on contacting the Lacks family, includes any plans to develop intellectual property or commercial products based on the findings, and that the research findings will be published or presented.

Publications that use the HeLa genomic data also must include the acknowledgement: “Henrietta Lacks, and the HeLa cell line that was established from her tumor cells without her knowledge or consent in 1951, have made significant contributions to scientific progress and advances in human health. We are grateful to Henrietta Lacks, now deceased, and to her surviving family members for their contributions to biomedical research​.”

Related news

Show more

Related products

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 05-Aug-2020 | Technical / White Paper

Traditional methods for adventitious agent testing rely on biological amplification and detection, which can take several weeks. This time-consuming approach...

Related suppliers

Follow us

Products

View more

Webinars